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an acute deterioration of renal function with a sudden rizc in serum 
creatniine concentration to more than 2 ing% 
Results: O f  thc 359 cases meeting case definition, the most 
frequent causes of ARF were: medical (60%) surgical (obstructive and 
postoperative, 33%). Among medical causes of ARE nephrotoxic 
agents accounted for 80 cases- 22%1:15 cases of interstitial nephritis 
due to rifampin, acute tubular necrosis due to aminoglycosides 21 
cases, following the use of radiographic media and metals 5 cases, due 
to henioglobinuria and myoglobinuria 31 cases, due to organic 
solvents 8 cases. In all cases of ARF due to rifampin, the drug was 
used i n  definitely diagnosed tuberculosis. In 13 cases ARF occurred 
abruptly within 48 h after a new antituberculous combination, 
including rifampin, in internmittent administration (dosages < 1200 
mg). Aniinoglycosides induced AKF in cases in which life-threaten- 
ing conditions, such as sepsis (6), endocarditis (1) and surglcal proce- 
dures (S), occurred. ARF was severe in all cases due to the above 
mentioned drugs demonstrated by: oliguria at adinission (urine 
output <400 mL/day in 18 cases), hematologic failure (21 with 
heinatocrit <30%), the need for dialysis (33 cases). All episodes of 
ARF due to rifampin recovered after conservative treatment or 5-12 
dialyIis (12 cases). Seven cases of ARF due to aminoglycosides were 
healed, in 2 death occurred, and in 13 cases the long-term outcome 
was not known. 
Conclusions: ARF is a rare and severe adverse effect of the 
discontinuation of rifampin therapy but it is not a cause of death, 
while the aminoglycoside nephrotoxity complicates the outcome of 
severe diseases. 
I P250 I Hepatic monooxygenase activities in juvenile 
rats after pre- and postnatal exposure to 
indinavir 
T.G. Schulz, B. Krause, K. Riecke, R. Stahlniann, E. Hallier. 
D e p r r i w ~ t  of Occupafional Health, Georg-Aigust- University Gor t inp t ,  
Gottirigen, Ckrniariy 
Background: Indinavir is an inhibitor of the HIV protease. Only 
limited data are available on the effects of indinavir on cytochronie 
P450-dependent monooxygenases, which are important enzymes of 
xenobiotic metabolism. The enzyme-modulating etfccts in the 
offspring after pre- and postnatal exposure to indinavir are completely 
unkown. 
Methods: Wistar rats were treated orally from day 9 of gestation 
until day 21 of lactation with either vehicle alone (starch solution, 
2%) or indinavir (500 nig/kg body weight once daily). From day 7 
postpartum on, 4 male and 4 female offspring of each treatment 
group were sacrificed weekly Microsonial fractions were prepared 
from liver and investigated for several monooxygenase activities such 
as niethoxy-, ethoxy-, pentoxy- and benzoyloxyresorufin O-dealky- 
lases (MROD, EROD, PROD, BROD). These enzyme activities are 
useful to detect CYP 1 A 1, CYP 1 A2, CYP2B2 and CYP3 A 1 in 
rat tissues. 
Results: EROD and MROD activities were low at postnatal day 
7 and increased during the following 6 weeks. PROD and BROD 
activities increased only moderately during postnatal development. 
However, no significant difhences were found between control and 
indinavir-treated rats for any of the enzymes investigated. 
Conclusions: These results gave no indication for an enzyme 
induction or inhibition by indinavir during the postnatal develop- 
ment with respect to CYPIA1, CYPlA2, CYP2B2 and CYP3Al 
under our experimental conditions. 
Ip251] Effects of protease inhibitors on pre- and 
postnatal development of rats 
K. Riecke, M. Shakibaei, I. Chahoud, R. Stahlmann. Irrstitiite of 
Clinical Plrarniucol~yy and %xicology, Bei@rnin Frariklin bfrdiral 
Cenfrc, Freie Unrversiriir Berlin, Germany 
Background: Indinavir and ritonavir are inhibitors of the HIV 
protease. Few data have been published on their reproductive and 
developmental toxicities. 
Methods: Teratology studies were performed on Wimr  rats 
treated orally with indmavir from day 9-1 1 of gestation (500 mg/kg 
b.i.d.) or day 6-15 (SOU nig/kg once daily) or vehicle (starch solu- 
tion 2%). At day 21, fetuses were explanted for skeletal evaluation. 
Postnatal studies were performed on rats treatcd from day 9 of gesta- 
tion until day 21 of lactation with either vehicle alone, indinavir or 
ritonavir (500 mg/kg once daily). Landmarks of postnatal develop- 
ment were monitored. From postpartal day 7 on, 10 male and 10 
female offspring of each treatment group were sacrificed weekly. 
Organ weights were taken, and tissue samples were collected for elec- 
tron microscopy 
Results: Fetuses showed several skeletal anonlalies such as addi- 
tional lumbar ribs and asymmetric ossification of vertebrae. 
Postnatally, body weight in otfspring treated with indinavir or riton- 
avir was decreased. At postnatal day 14, the indmavir-treated 
oEspring had a lower relative liver weight when compared to 
controls. In both the indindvir (7/347=2%) and in  the ritonavir 
(1 /6Y) groups, offspring with unilateral anophthalniia were observed 
at day 18. 
Conclusions: These results suggest that HIV protease inhibitors 
should be used carefully in women who are pregnant or who could 
become pregnant during the treatment (post-exposure prophylaxi?) 
until further data are available from their use in pregnancy. The sinii- 
larity of the protease inhibitor binding site to the  retinoic acid recep- 
tor adds to this concern. 
Community acquired pneumonia 
Evaluation of serologic response to Coxiella 
burnetii in patients with atypical pneumonia 
I? Karaboyia-Karafillidis, E. Vagiakou-Voudris, C .  Kakkari, A. 
Souras, D. Mylona-Petropoulou. Microbiology Laborarory, IVutiiirial 
Rubella Reference Center, Gerreral Disrrirr Huqiral ‘C. C;ewiniaras’, 
Athens, Grtwe 
Objectives: To evaluate the role of Cuxiella burrzetii in cases of atyp- 
ical pneumonia in adults at a district general hospital. 
Materials and methods: Blood samples were collected from 1 50 
patients (1 10 men, 40 women age 18-60 years old) hospitalized with 
atypical pneumonia in the General District Hospital of Athens. The 
diagnosis of atypical pneumonia was based on the clinical picture, the 
chest X-ray and the serologic study. The serologic study for Ckxiella 
burnetii was based on an indirect ininiuiiofluorescence tect. The crite- 
ria for acute infection from Coxiella burnctii were (1) phase 11 IgG titer 
=1/512, (2) phase I1 IgM =1/20 and or seroconversion. 
Results: Only 13 of the 150 patients were (8.66%) found to be 
seropositive for IgG antibodies to Coxidla burnetii at a titer of 1/31 2 
or more. IgM antibodies were detected in 9 out of the 13 patients 
with positive IgG antibodies (9/150, 6%). Seroconversion was found 
in 3 of the patients. 
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Conclusions: Our results suggest that Coxiella burnetii was 
responsible for 8.66% of the cases of atypical pneumonia among the 
150 hospitalized patients in the General District Hospital of Athens. 
m] Anaerobes in pulmonary infection 
K. Schulzl, H. Bernhardt’, H. Wendel’, M. Wiersbitzky’, S .  
Patten’. Clinic o/ lnternal Medicine ‘A, 2B, University of Greijiwald, 
Creijiwald, Germany 
Objectives: We evaluated microbiologicalal findings of bronchial 
secretions from patients with pulmonary infections especially in order 
to study the role of anaerobes in inflammatory airway diseases. 
Methods: 165 bronchial secretions had been obtained using 
protected specimen brush. The microorganisms had been cultured 
under aerobic and anaerobic (glove-box method) conditions. The 
average time between the sampling and the microbiologicalal proce- 
dure was 11 min. The patients had been classified into therapeutic 
and diagnostic groups. 
Results: 33% (54/165) of the specimens were colonized with 
anaerobes (1 12 strains). Anaerobes were more often detectable in 
samples from patients without antibiotic treatment prior to. the 
procedure (40%, 36/89) than in those with antibiotic treatment (24%, 
18/76). The main isolated anaerobic strains were Gram-negative rods 
(40%, 45/112) followed by Gram-positive rods (34%, 38/112). 6% 
(10/165), above all in aspiration pneumonia and exacerbation of 
chronx obstructive pulmonary disease (COPD), showed significantly 
positive anaerobe cultures (= log 3 CFU/mL). One of these 10 
cultures was a pure anaerobe. Concerning positive anaerobe cultures, 
there was no difference between ventdated (31% 10/32) and non- 
ventilated patients (33% 441133); 9% (3132) of the ventilated and 
5% (7/133) of the non-ventilated patients showed germ counts of 
anaerobes=log 3 CFU/mL. 
Conclusions: Anaerobes as pathogens are rare in pulmonary 
infections, but they have to be considered for patients with aspiration 
pneumonia, or exacerbation of COPD, and for ventilated patients 
with pneumonia. 
Does PCR help laboratory diagnosis of 
Legionella spp.? 
K. Jaton-Ogay, J. Bille, A. Telenti, C. Pktignat, J. Zufferey, A. 
Wenger, Centre Hospitalier, Universitaire kudois ,  Lausanne, 
Switzerland 
Objectives: To evaluate the contribution of PCR to the laboratory 
diagnosis of Legionella spp. in comparison with culture. 
Methods: Over a 2-year period, 150 respiratory tract specimens 
(78 patients) sent to the laboratory for Legionella spp. culture were 
submitted to PCR. Culture was performed on selective BCYE agar 
incubated for 14 days. PCR was carried out using primers directed 
at the 16s rRNA gene followed by ELISA detection of the ampli- 
fied products aher hybridization to biotin- and digoxigenin-labeled 
probes. 
Results: Thirteen specimens (7 patients) were positive for 
Legionella pneumopkila serotype 1 (5 cases) and serotype 10 (2 cases) 
by both culture and PCR. A further eight specimens from the same 
positive patients were negative by culture but positive by PCR; four 
of them were from one patient with suspicion of legionella pneu- 
monia relapse and the other four specimens were bronchoaspirates 
with concomitant BAL positive by culture. Twenty-four cultures (13 
patients) were inconclusive because of overgrowth of other bacteria 
on the BCYE in the first days of incubation. PCR was negative for 
22 of them (12 patients), whereas it was positive for two specimens 
(1 patient). No additional case was detected by PCR in the 113 
culture-negative specimens (58 patients). 
Conclusions: PCR was a useful additional tool for the laboratory 
diagnosis of Legionella spp. because it gave a rapid preliminary report 
and was more sensitive than culture. Moreover, it was more suitable 
than culture in contaminated specimens. 
m1 Legionella sainthelensi serogroup 2 isolated 
from a patient with pneumonia 
M.C. BCzianl, A.M. Gavinet’, Hernandez2, B. Dubad, S. 
Winnock’, J. Etienne3. ‘Laboratoire de Bactiriologie, 2Dipartement 
d‘Anesfhbie-Rhanimation, H6pital Saint-Andd, Bordeaux, 3Laborafoire 
de Microbiological CNR des Ggionelles, Lyon, France 
Objectives: To present a case of pneumonia due to L. sainfhelensi 
serogroup 2. 
Methods: The patient, an 86-year-old man, was first admitted to 
the hospital for angiocholitis treated by ceftriaxone and metronida- 
zole, and later, in the intensive care unit, for a severe pneumonia with 
hypoxemia. At that time, ciprofloxacin was added. He died on the 
7th hospital day with refractory septic shock and acute respiratory 
distress. 
Results: Direct immunofluorescent testing and biochemical char- 
acteristics of the strains isolated from the two bronchial washings 
allowed us to identify a non-pneumophila Legionella strain closely 
related to L. saintkeiensi. The results of DNA analysis (RAPD and 
ISR-PCR (intergenic 16s-23s gene amplification)) were essentially 
typical of L. sainthelensi serogroup 2 strain. O n  the one hand, the 
search for L. pneumopkila-specific antibodies was negative, and on the 
other hand, no specific urinary antigen was found. The search for 
Legionella in the patient environment, particularly in moist areas and 
in air-conditioning, in hospital and in domestic samples was nega- 
tive. 
Conclusions: We report a case of pneumonia due to L. sainthe- 
lensi serogroup 2, which is exceptionally associated with this human 
disease . 
lp2561 NASBA inhibitors in respiratory Specimens 
K. Loens, D. Ursi, M. Leven, P. van Aarle, P. Oudshoorn, H. 
Goossens, University ofrfntwerp, Medical Microbiology, Wilrijk, Belgium 
Objectives: DNA and RNA amplification methods on clinical 
material may produce false-negative results, due to inhibition of 
amplification. The aim was to detect nucleic acid sequence-based 
amplification (NASBA) inhibitors in respiratory specimens and to 
develop an optimal specimen treatment procedure. 
Methods: Respiratory specimens were spiked with known 
amounts of M. pneumoniae cells and several sample treatment proce- 
dures were used to eliminate inhibitors; dilution, modified nucleic 
acid extraction procedures, and treatment with N-acetyl-L-cysteine 
and proteinases at different temperatures and concentrations. 
To detect NASBA inhibitors for different types of specimens, 10 
of each were selected. The color, viscosity and presence of blood or 
hemolyzed blood were recorded and the samples were spiked with 
known numbers of M .  pneumoniae cells and treated. 
Results: The respiratory specimens became more fluent with all 
the methods tested. Only one procedure, the protease treatment in 
combination with a lower pH during nucleic acid extraction, 
improved the detection level. Five very viscous respiratory specimens 
were inhibitory to amplification. The presence of blood or 
hemolyzed blood did not influence the amplification. 
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Conclusions: In our experience, treatment of respiratory speci- 
mens with protease for 30 miii at 25OC produces the best results. 
Viscosity of the respiratory specimens seems to be a major inhibitory 
factor for NASBA amplification. 
[p257) NASBA development for detection of 
Mycoplasma pneumoniae 
K. Loens, D. Ursi, M. Leven, l? van Aarle, P. Oudshoorn, H. 
Goossens, University o f h t n i e r f i  Medical Microbiologx Wilrijk, Belgium 
Objectives: Mycoplasma pneumoniae is an etiologic agent of respira- 
tory tract infections in humans. In the past, diagnosis of infection by 
this organism was based on serology because culture is slow and 
insensitive. Therefore, nucleic acid sequence-based amplification 
(NASBA) might offer an alternative. The aim was to develop NASBA 
for detection of M .  pneumoniae 16s rRNA in respiratory specimens, 
compare it with P C R  targeted at the P1 adhesin gene, and develop 
wild-type R N A  and an internal control R N A  (IC). 
Methods: Primers and probes were designed. To assess the sensi- 
tivity of the assay, a plasmid was constructed generating the M.  pnen- 
moniae 16s rRNA. A modified plasmid was constructed to generate, 
with the same primer set, the internal control. Serial dilutions of M.  
pneumoniae and IC, wild-type R N A  and IC were added to different 
types of respiratory specimens. The RNA was extracted and anipli- 
fied by NASBA, and the amplification products were identified by 
an enzyme-linked gel assay. The same specimens were subjected to 
PCR. 
Results: The sensitivity of NASBA was determined at 10 mole- 
cules of wild-type RNA or 2.5 M.  pneumoniae cells. The sensitivity 
of NASBA for detection of M .  pneumoniae in spiked respiratory spec- 
imens, in the presence of the IC, was 1000 molecules of wild-type 
R N A  or 25 M.  pneumoniae cells. The sensitivity was comparable to 
that of PCR. Finally, 13 clinical specimens positive for M .  pneumo- 
niae were confirmed by NASBA. 
Conclusions: These results show that NASBA is suitable for 
amplification of M.  pneunioniae rRNA in clinical specimens. 
[p258) Clinical evaluation of the management of 
community-acquired pneumonia (CAP) by 
general practitioners (GPd in France 
B. Fantin', EURAXI', SFTG', C. Carbon'. 'INSERM U 13, 
Paris, 'Network for the study of CAI: France 
The management of CAE' by GP was prospectively investigated 
between October 1995 and March 1997 in 11 French counties. A 
chest X-ray confirming the clinical suspicion of CAP was requested. 
130 patients were included by 50 GPs. Mean age was 52 (18-90). 
27% of the patients were 65, 52% had a co-morbid illness, and 18% 
had already received previous antibiotherapy. 13 patients (10%) were 
hospitalized at the initial visit. Among the 117 remaining patients 
(90%) with ambulatory management, the choice of the initial antibi- 
otic prescription was in accordance with the 1991 French reconi- 
mendations in 49% of the cases. There was no relationship between 
the choice of antibiotic precription and the presence of a co-morbid 
illness or an age of 65. 75/117 patients (64%) were cured without 
change of antibiotic therapy or hospitalization. 33 patients (28%) 
required a modification of the initial antibiotic prescribed, and 9 
patients (8% were secondarily hospitalized. These hospitalizations 
were due to an inadequate antimicrobial treatment in 3 cases, 
pulmonary embolism mimicking CAP in 3 cases, and underlying 
diseases in 3 cases. Among the 22 hospitalized patients, 5 (23%) died 
because of an underlying disease. We conclude that adherence of 
antibiotic prescription of GPs to national recoiiimendations is poor. 
However, hospitalization due to inadequate antibiotic therapy of 
ambulatory CAP occurred in only 3/117 cases (2.6%). 
m1 Influence of socio-economic status on the 
features and outcome of community-acquired 
pneumonia (CAP) 
S .  Stelianides', J.L. Golmard', C. Carbon', 13. Fantin'. 'Iiztcrrial 
Medicine, Bichat and Beanjon Hospitals 'Biostatistics, P itil.-Salp&rii.rc 
Hospital, Paris, France 
Objectives: To investigate the influence of low socio-economic 
status (SES) on the features and outcome of CAP. 
Methods: Study of 107 consecutive patients hospitalized for CAP 
in a department of interiial medicine. A low SES was defincd by the 
presence of at least one of the following conditions: long history of 
unemployment, honielessness, &ee medical supply, governmental 
supply as the only resource, crowded living conditions. 
Results: Thirty-four patients (32%) were considered ac having a 
low SES. These patients were more likely to be immigrants, middle- 
aged, with less co-morbid illnesses, and were more often tobacco, 
alcohol or drug consumers (P<O.Ol), as compared with the 73 other 
patients. The distribution of etiologies waF significantly diffcrcnt 
according to SES, with more frequent tuberculosic in the low-SES 
group @<0.05). The severity of CAP was similar in patients with or 
without low SES, as was the clinical outcoiiie in ternis of transfer to 
the intensive care unit or mortality. However, low SES was an inde- 
pendent factor that significantly prolonged the length o f  hospitaliza- 
tion by6 days (5.9 days, 95% confidence interval: 2.2-9.5 day,  
p<0.003), entailing a substantial excess cost per hospital stay, and 
showing the lack of adequate structures for management. 
Ip2601 Hospital-based survey: pneumococcal 
pneumonia among hospitalizations by 
pneumonia 
J.M. Bayas', A. Vilella', A. Gonzilez', M.J. Bertrin', C. Adell', X. 
Rojano' . 'Preventive Medicine, Hospital Clink, Barcelona, 'Medical 
Department, Pasteur Merieux MSD, Madrid, Spain 
Objectives: To assess the frequency and characteristics of patients 
hospitalized by pneumococcal pneumonia among the total of adnn-  
sions by pneumonia (ICD-9-CM 481-486) in an 850-bed general 
hospital. 
Methods: Hospital-based retrospective study All patients with 
hospital discharge diagnosis of pneumonia due to any cause (IC13-9- 
C M  481486;  as first listed diagnosis) were identified over a I-year 
period (1996). Medical records were reviewed for those patients with 
a diagnosis of pneumococcal pneunionia (ICD-9CM 48 1). 
Results: A total of 647 patients with discharge diagnosis of pneu- 
monia due to any cause were identified. Mean age (91) and 
male/female ratio were 67 (18.5) years and 64%/36% respectively 
Sixty-five per cent of the patients were aged 65 years or more. 
Average length of stay (ALOS) and mortality rate were 10?9 days 
and 11% respectively. Etiologic diagnosis was not determined in 87% 
of the cases. Pneuniococcal pneumonia was confirmed in 34 patients 
(40% of patients with etiologic diagnosis). Mean age (SD) of this 
group ofpatients was 56 (17) years (38% were aged 65 years o r  older). 
ALOS and mortality rate were 15214 days and 9% respectively. Rlsk 
factors for pneumonia included chronic obstructive pulmonary 
disease (38%) or chronic liver disease (22%), alcoholism (21%) and 
cardiovascular diseases (1 6%), among others. 
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Conclusions: Pneumonia is an important cause of hospitaliza- 
tion, being responsible for almost two admissions per day in an 850- 
bed hospital. Etiology was determined in 13% of cases. The most 
common pathogen was S. pnerrmoniae (40%). 
Conclusions: The monitoring of trends of the bacterial resis- 
tance in CAP has important consequences for empirical antibiotic 
therapy. 
Hospitalizations by pneumonia: epidemiologic 
data 
A. Gil’, A. Gonzalez’, J. Esteban’, J.C. Ansede’, C. Lttpez’. 
’Preuentiue Medicine, School .f Medicine, Complutense University, 
’Medical Department, Pasteur Mbrieux MSD, Madrid, Spain 
Objectives: To obtain epidemiological data of patients hospitahzed 
by pneumonia due to any cause (ICD-9-CM 481-486) in a 1200- 
bed general hospital. 
Methods: Hospital-based retrospective study. All patients with a 
hospital discharge diagnosis of pneumonia (ICD-9-CM 481-486; as 
first listed diagnosis) during 1996 were identified, and medical 
records of all these patients were reviewed 
Results: A total of 763 patients with discharge diagnosis of pneu- 
monia due to any cause (ICD-9-CM 481-486; as first listed diagno- 
sis) were obtained. Mean age (SD) and male/female ratio were 62 
(26) years and 62%/38% respectively. Sixty per cent of the patients 
were aged 65 years or more and 6% were younger than 5 years of 
age. Average length of stay (ALOS) and mortality rate were 14210 
days and 14% respectively. Risk factors for pneumonia included 
chronic obstructive pulmonary disease (38%), chronic liver dsease 
(22%), alcoholism (21%) and cardiovascular diseases (16%), among 
others. Pneumococcal pneumonia (ICD-9-CM 48 t) as first diagno- 
sis was mentioned in 509 cases; however, this diagnosis was 
confirmed in only 8 patients. Microbiologicalal diagnosis was estab- 
lished in 40 pneumonia cases: the main organisms involved were S. 
pneumoniae (20%), S. anreus (20%), Mycoplasma (17.5%), Pseudomonas 
(17.5%) and H. irzjluenrae (7.5%) 
Conclusions: Pneumonia is an important cause of hospitaliza- 
tion, being responsible for more than two admissions per day in a 
1200-bed public hospital. Pneumococcal pneumonia seems to be the 
most common cause of hospitalization by pneumonia. However, 
nlicrobiologicalal confirmation was only done in 1% of the cases, the 
most common pathogens being S. pneumonioe and S.  aurens. 
(p2621 Etiology of community-acquired pneumonia in 
hospitalized adults 
B. Girgitzova’, S.T. Milanov’. ‘Department .f Clinical Microbiology, 
’Department .f Internal Medicine, Emergency Medical Institute ‘Piropu’, 
Sofia, Bulgaria 
Objectives: To characterize the pathogens isolated from patients 
with community-acquired pneumonia (CAP) requiring hospitaliza- 
tion. 
Methods: The study includes 321 patients, age range 16-85, 
admitted for treatment to the Department of Internal Medicine in 
the periodJuly 1996 to June 1998. The etiologic agents were deter- 
mined in sputum, pleural fluid and blood cultures and by serologic 
testing. 
Results: Pathogens were identified in 194 (60.4%) of the patients. 
The most common pathogen was S. pnelrmoniae (73 patients), 
followed hy Pseudomorias 23, group KES-39. Among the pneumo- 
coccal strains, 28.4% were non-susceptible to penicillin. S.  aureus was 
isolated in 10 patients (in 7 MRSA). In 8 cases, pneumonia was 
caused by H .  intuenzae; in 4 cases it was associated with Chlamydia 
spp. Viral infection was diagnosed in 16 of the patients. 
I P263 I Community-acquired pneumonia in a general 
hospital. Epidemiologic changes, clinical 
patterns, prognostic factors and influence of 
treatment in the evolution. Comparative and 
prospective study 1991-97 
M.E. Sinchez, J. Gbmez, J. Gbmez Vargas, V. Banos, J. Ruiz, L. 
Munoz, E. Simarro, M.C. Soto, M. Cameras, M. Valdis. University 
Hospital ‘Virgen de la Arrixaca’, Murcia Srhool .f Medicine, Muirin, 
Spain 
Introduction: Community-acquired pneumonia (CAP) is one of 
the most important infectious problems due to its high morbidity and 
mortality and difficulty in the diagnosis and treatment. 
Objectives: To study the clinical and epidemiologic patterns, 
prognostic factors and influence of treatment, in order to establish 
useful and rational protocols. 
Patients and methods: We conducted a prospective study of409 
patients admitted between 1991 and 1997 and diagnosed with CAP 
according to classical criteria. By non-invasive methods, CAP was 
divided into typical or atypical. All pertinent clinical and epidemio- 
logic data were routinely collected. For prognosis, the severity of the 
underlying disease, the initial clinical status, the type of microorgan- 
ism, the presence of complications and the treatment used were 
recorded. The patients were given, alternately, cefuroxime, amoxy- 
cillin-clavulanic acid in high doses or ceftriaxone, and were followed 
clinically, radiologicly and nlicrobiologically during treatment, at the 
end of treatment and between 1 and 6 months after discharge. A 
Pearson Fisher test and multivariate analysis were done. 
Results: 59.6% of the patients were male. In 63% an underlying 
disease was found, cardiovascular being the most frequent (54.3%), 
followed by alcoholic hepatopathy (23%), diabetes in 17.4%. AVE in 
5.9% and nephropathy in 2.4%. 52.08% of the patients had lower 
respiratory tract infections and 50.1% received antibiotics in the 
preceding 6 weeks. 39.6% cases were documented microbiologically, 
S.  ptzeumoniae being the most frequent at 52.4%, followed by H. 
injluenzae in 18.5%, C. pneumoniaein 14.8%, A4. pneumoniae in 6.7%. 
L. pweumophila in 4.396, S. aureus in 1.8% and M.  catarrhalis in 0.6%. 
We found a lower rate of atypical microorganisms in the period 
1994-97, compared with the 1991-94 period. Clinically, in univari- 
ate analysis, we found that male gender, COPD, fever, mucopuru- 
lent sputum, regular clinical situation and heart fadure were 
significantly associated with documented CAE In the multivariate 
analysis, only fever and heart failure were significantly associated. The 
non-documented CAP were with previous respiratory infections and 
previous use of antibiotics, gastrointestinal abnormalities, abnormal- 
ities of mental status and liver function and poor initial status in 
univariate analysis. In multivariate analysis, only the previous respi- 
ratory tract infections, and the gastrointestinal and liver function 
abnormalities were significantly associated. The typical CAP was 
significantly associated with age 65 years, diabetes, cardiopulmonary 
disease, mucopurnlent sputum, pleuritic pain, pulmonary infiltrate 
and sed rate 50 mmHg were found. The atypical ones were associ- 
ated with smoking, arthromyalgia and heart failure, although only 
heart failure was significantly associated in multivariate analysis. 
Prognostic factors associated with higher mortality were, we found, 
bilateral pulmonary infiltrates, respiratory and renal failure, shock and 
poor response to treatment. 206 patients received cefuroxime, 105 
ceftriaxone and 98 amoxycillin-clavulanic acid; the groups were 
similar and without differences in efficacy. 
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Conclusions: A knowledge of the clinical and epidemiologic 
patterns is very important m the rational approach to CAP. 
Anioxycillin-clavulanic acid is probably the most rational initial alter- 
native in such cases, that could be associated with macrolides accord- 
ing to local epidemiology data. 
lp2641 Epidemiologic survey: hospitalizations by 
pneumonia in Spain 
V. Merge', A. Gonzalez'. 'Preventive Medicine, Hospital Ranzott y 
Cajal, Uttiversify of Alcala, 'Medical Department, Pasieur Merieux 
MSD, Madrid, Spairi 
Objectives: To study the epidemiology and etiology of patients 
requiring hocpitalization by pneumonia (ICD-9-CM 4 8 W 8 6 ;  as 
first listed diagnosis). 
Methods: Descriptive retrospective study. Data were obtained 
from a total of 258 public hospitals (77% of hospitals included in the 
National Health System) for the 1995-96 period. All patients with 
hospital discharge diagnosis of pneumonia (ICD-9-CM 480-486; as 
first listed diagnosis) were identified, and epidemiologic data (age, 
sex, diagnorir, length of stay and outcome) were obtained. 
Results: A total of 106 176 cases of pneumonia (ICD-9-CM 
480-486) were identified. The distribution of patients by age group 
was: <5 years (14.5%), 5-24 years (8%), 25-39 years (lo%), 40-59 
years (12'%), 60-79 years (34%), and =80 years (21%). Male/female 
ratio was 63%/37%. The average length of stay (ALOS) was 11 k 10 
days: < = 10 days in 63% of cases and < =20 days in 90% of cases. 
Global mortality rate was 7%. Main etiologic diagnoses were: 
Conclusions: Pneumonia is an important cause of hospitalization 
in Spain. Pneumococcal pneumonia accounted for 25% ofthe annual 
pneumonia cases requiring hospitalization and for almost 80% of cases 
with etiologic diagnosis. 
[p2651 Asthma, macrolides and Chlamydia 
pneumoniae 
P. Rainos, L. Arrieta, 11. Pala, R. Resines, J. Samaniego, E. 
Sagredo. Pliarmary Faculty, University .f Bask Country, Vitoria, Spain 
Objectives: To measure in asthmatics' titers of IgC to Chlamydia 
pneimoniae, forced expiratory volume in 1 s (FEV1) and acute 
episodes (AE), before and after (3-tnonth) roxithrornycin treatment 
(300 mg orallylday for 21 days). 
Methods: 40 mild and moderate asthmatic patients were distrib- 
uted in two groups: A1 (n=20, mean age 3728 years) andA2 (~1=20, 
mean age 3 8 2 9  years). The control group (C) comprised healthy 
persons (n=20, mean age 3828 years). The A2 group was treated 
with roxithroniycin; the A1 and C groups received placebo. Before 
treatment and 3 months later we measured titers of 1gG to Chlamydia 
pneumonia? (indirect inmunofluorescence test, MRL diagnostic, 
EEUU), FEVl (with spirometer) and AE (acute episode symptoms 
and duration). Statistical analysis: Student's t- and chi-squared test. 
Results: Before treatment. FEVl was 2.2450.28, 2.28k0.33 and 
3.9520.25 L/sg for the Al ,  A2 and C groups respectively (between 
both asthmatic groups there was no significant difference; between 
acthniatics and the C group p'0.05). After treatment, FEVl in the 
A2 group increased 15.7'X and was higher than that in A1 
(2.65t0.37, 2.2650.29 L/sg; p<0.05). There was no change in the 
C group (3.9120.21 L/sg). 1gG titers=l:lh in both samples were 80 
in the A1 group, 75 in the A2 group and 55 in the C group. IgG 
titers=l:lh during 3 months or more, suggesting chronic or past 
Chlamydia prieuniuniatz infection. Both asthmatic groups had more 
patients in this situation than the control group (p<0.01, chi-squared 
test). I n  28 patients of the A2 group we observed a decrease of IgG 
titers in the second saniple (two or more fold, e.g. from 1:64 to l:l6), 
This effect is related to treatment lp<O.O5, chi-squared test). AE: for 
the first sample there was no difference between the A1 and A2 
groupc ( I  ,3520.34 and 1.42&37 acute episodrs/person/3 months). 
For the second sample, A1 was higher than A2 (1.1120.31 and 
0.58k0.19 acute episodes/person/3 months; p<O.O5). Thir effect is 
related to anti-inflammatory and bactericidal roxithroniycin action. 
Conclusions: 75-80 asthmatic patients and 55% of controls had 
IgG to Chlarnydia prtenmoniar titers= 1:16 during 3 months jp<O.O5 
chi-squared-test). Patients treated with roxithromycin had reduced 
IgG titers (inside chronic interval), increased FEVl ( I  5%) and less 
AE . 
lp266( Chlamydia spp. antibodies in lower respiratory 
tract infections 
A. Uurova, V. Malikov, V Nonikov, T. Konstantinova, 0. 
Makarova. Central CIinical Huspilal, Mostuiu, Russia 
Objectives: To describe the incidence of chlamydia scroloby in  
lower respiratory tract infections (LRTI). 
Methods: Case series September 1997 to September 1998 in 
Moscow. Patients with comniunityacquired pneumonia (CAP), 
acute exacerbation of chronic bronchitis (AECB). Study using 
enzyme-linked innnunosorbent assay (ELISA) to detect IgM, 1gG and 
IgA antibodies to Clrlanrydia spp. 
Results: Chlamydia seroloby (1gM) was positive in 441324 
(13.6%) of CAP patients and in 16/154 (10.4%) of patients with 
AECB. 
Conclusions: These results confirm that Chlamydia has an  impor- 
tant place aniong the etiologic factors of LRTI in Russia. 
[p2671 Adult respiratory distress syndrome, 
autoimmune hemolytic anemia and bilateral 
sensorineural hearing loss in a patient with 
Mycoplasma pneumoniae infection-a case 
report 
H. Yanardag', M. Bilir', S. Sipahi', K. Midilli', T. Karayel'. 
I Inicrttai Medicine Depariment, 2A4icvobiolq~ Department, Cerrahpaza 
Srl iool i!f Mrdiciric, KMP-Istanbul, Turkey 
A 38-year-old female prerented to our department with abrupt onset 
of dyspnea, cough, high-grade fever and bilateral hearing loss. The 
findings of her physical examination were consistent with pneuiiio- 
nia accompanied by ARDS. The analysis of blood gases revealed 
ARDS (pOz 40 iiiniHg, pCOz 40 mmHg). Hematologic examina- 
tions were consistent with acute infection and hemolytic anemia. 111 
serologic examinations anti-M. pneumoniae IgG and 1gM antihodie, 
were found positive. Cold agglutination test was positive at 1:56. 
Chest radiogram was consistent with hilateral interstitial involvriiirnt 
of the lower lung lobes. Audiometric and tympanoinetric exanlina- 
tionr revealed moderate sensorineural hearing loss. 
Pneumonia due to M. pneumonia? 1v3s diagnowd and clar- 
ithroniycin (2X 500 nig, oral) treatment was initiated. 
Following the initiation of the treatment, blood gases returned to 
normal levels on  the 7th day, and the chesc radiogram and heniato- 
logic parameters on the 20th day. At 1 month the hearing lore 
completely disappeared. 
To the best ofour knowledge, this is the first M.  pneunioniae pneu- 
monia case complicated by a combination of ARUS, autoinmltnie 
hemolytic anemia and sensorineural hearing loss. 
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[p2681 Levofloxacin in the management of CAP due to 
PRSP and DRSP 
J. Kahn, B. Wiesinger, M. Khanna, Ortho-McNeil Pharmaceutical, 
Clinical Af i irs ,  Raritan, NJ, USA 
Levaquin (L) (levofloxacin) is approved for mild-moderate to severe 
community-acquired pneumonia (CAP) caused by Streptococcus pneu- 
moniae, Staphylococcus aureus, Haemopltilus injuenzae, Haemophilus 
parainjuenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia 
pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae. Clinical 
trials have established that once-daily dosing with 500 mg of oral or 
parenteral L achieves clinical cure rates that are at least the equivalent 
of traditional antimicrobial agents, many of which need to be dosed 
several times a day, lack bioequivalent oral and parenteral formula- 
tions, or have to be administered with a second agent. Recent reports 
have established L’s etficacy in cases of CAP attributed to penicillin- 
resistant pneumococci (PRSP). In one of these, L achieved clinical 
success rates of 100% in cases caused by PRSP strains of several 
phenotypes, including a number (N= 13) that showed high-level 
resistance to penicillin (MIC equal to or greater than 2 mg/L). 
The current open-label, non-comparative, multicenter trial is 
designed to recruit additional patients with infections due to PRSP 
or multiply-resistant pneumococcal strains (DRSP). Through early 
November 1998, more than 500 cases had been enrolled and the 
study will continue to the end of the 1998-99 respiratory tract infec- 
tion season. At least two clinically and microbiologically evaluable 
cases of fully resistant PRSP have been identified to date and success- 
fully treated with L. Data updated through February 1999 will be 
presented on overall clinical success rates, microbiologicalal eradica- 
tion rates for all isolated pathogens and several DRSP phenotypes in 
particular, and adverse events. 
While the clinical significance of PRSP and DRSP remains a 
subject of debate, this study confirms that 500 mg once-daily dosing 
of L remains an effective therapy for CAP caused by these organisms 
as well as those previously indicated. 
lp2691 A phase IV open comparative randomized 
multicenter study of spiramycin versus 
clarithromycin in the treatment of lower 
respiratory tract infections 
V Kasak, J. Devai, J. Lukacs, G. Nagy, P. Kuna, K. Oklek, A. 
Sliwowski, Y. Novikov, L. Stratchounski, S. Yakovlev, L E R Y M E D ,  
Respiratory Disease, Prague, Czech Republic 
This international study compared the efficacy of oral spiramycin 
(3 MU1 bid . )  versus oral clarithromycin (500 mg b.i.d.) for 7-10 
days in the treatment of non-complicated lower respiratory tract 
infections (LRTI). LRTI diagnosis relied on the presence of at least 
four of the eight following symptoms: fever 38OC, chills, thoracic 
pain, abnormal chest auscultation, chronic bronchitis, appearance or 
increase of cough, or dyspnea, or purulent sputum. In cases of 
suspected pneumonia, a chest X-ray was obtained within 72 h. The 
main efficacy criterion was ‘success’ defined as no further antibiotic 
therapy required and each sign or symptom returned to normal or 
baseline level or improved a t  the end of treatment (4 -7 days after last 
drug intake). From March to December 1997, a total of 196 patients 
(114F/82M; mean age=50 years) were included in the Czech 
Republic (40), Hungary (36), Poland (60) and Russia (60): 99 
patients in the spiramycin (S) group and 97 in the clarithromycin (C) 
group. One hundred eighty patients completed the study: 89 patients 
in group S versus 91 in group C. At the end of treatment the major- 
ity of patients were classified as ‘success’: 84/99 (85%) in group S 
versus 88/97 (91%) in group C, with no significant difference 
between treatment groups (P=O.21). Adverse events (AE) were 
reported by 9/99 (9.1%) in group S versus 14/97 (14.4%) in group 
C. Five patients discontinued the treatment because of AE occur- 
rence: 2 patients in group S (diarrhea (1); headache (1)) versus 3 
patients in group C (urticaria (2); diarrhea (1)). The most frequent 
AEs reported were bitter taste (2 In group S versus 8 in group C) and 
diarrhea (3 in group S versus 6 in group C). The results of this study 
demonstrate that spiramycin is as effective as clarithromycin in the 
treatment of non-complicated lower respiratory tract infections. So, 
due to its spectrum covering the majority of respiratory pathogens, 
high tissue concentration and good efficacy, spiramycin appears to be 
well placed in the first-line treatment of LRTI. 
Im1 Appropriateness of initial antibiotherapy in 
community-acquired pneumonia 
0. Lamy, G. van Melle, B. Burnand. University Hospital, Lausatine, 
Switzerland 
Objectives: It is uncertain whether two drugs (addition ofmacrolide 
(m) to penicillins @) or cephalosporins (c)) are superior to one (c. p 
or m) as initial treatment of inpatients with community-acquired 
pneumonia (CAP). The aim of the study was to compare current 
practice with guidelines (GL) that specify which drug regimen should 
be used. 
Methods: Initial antibiotherapy received by the 152 CAP cases 
treated in 1997 at a teaching hospital was compared with a GL devel- 
oped in 1998. The GL proposed a two-drug regimen in the presence 
of legionnaires’ disease or in severe cases (hypotension, tachypnea or 
renal failure). 
Results: Median age was 74; 87 patients were male, 21 were 
admitted to ICU, and 7 died during hospitalization. Agreement 
between current practice and GL was low (kappa: 0.16); in 53/80 
patients who initially received two drugs, treatment was inappropri- 
ate according to GL (‘overuse’). Ofthe 71 patients who received one 
drug, 12 (17%) should have received two (‘underuse’). Among the 
20 Fine’s severity criteria, only tachypnea (> 30/min; P<0.001) and 
tachycardia (> 125/min; Pi0.05)  predicted correct use of two 
antibiotics. 
Conclusions: In this group of inpatients, following the proposed 
GL would have led to a decrease of 51% in the use of two antibiotics 
as the initial CAP treatment. This GL will require prospective vali- 
dation. 
[p2711 Efficacy and toleration of once-daily 
azithromycin versus twice-daily clarithromycin 
in adult community-acquired pneumonia 
D. Pontani, G. Treadway, the Azithromycin Pneumonia Study 
Group, @zer Pharmaceuticals Group, New York, Ny USA 
Background: The unique pharmacokinetic profile of azithromycin 
supports once-dally dosing for 3 days. Short-course therapy may 
promote compliance versus longer, multiple-daily regimens. 
Methods: Patients with mild-to-moderate community-acquired 
pneumonia were randomized in a multicenter, open-label, compar- 
ative study to receive azithromycin, 500 mg 0.d. for 3 days, or clar- 
ithromycin, 250 mg b.i.d. for 10 days. Patients were clinically and 
bacteriologicly evaluated at end of therapy (day 10) and at follow-up 
(day 28). Adverse events were recorded throughout. 
Results: 142 patients were randomized to treatment (72 
azithromycin, 70 clarithromycin). At day 10, clinical success (cure or 
improvement) was recorded in 53/54 (98%) and 52/57 (91%) of 
evaluable patients receiving azithromycin and clarithromycin, respec- 
A b s t r a c t s  
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tively. 85% of baseline pathogens were eradicated in patients treated 
with either azithromycin or clarithromycin. By day 28, all 47 evalu- 
able azithrotnycin-treated patients had been successfully treated, 
compared with 46/49 (94%) who received clarithromycin. All base- 
line pathogens were eradicated from evaluable patients in the 
azithromycin treatment group, but only 83% of those in patients who 
received clarithromycin. Treatment-related adverse events were 
reported in 10 (14%) azithroniycin patients, and 11 (16%) who 
received clarithromycin. These were mainly gastrointestinal, and mild 
to moderate in intensity. One clarithromycin patient mscontinued 
treatment due to an adverse event. 
Conclusions: Three-day once-daily azithroniycin is as effective 
and well tolerated as 10-day clarithromycin given twice daily in adults 
with community-acquired pneumonia. 
Lp2721 Meropenem versus imipenem/cilastatin in the 
treatment of community-acquired pneumonia 
in elderly patients 
A. Pozzi, P. Cravarezza, L. Sleiman, P. Donati, P. Prometti, M.C 
Tusi, G. Ravizzola, L. Franchino, G. Romanelli. Departments vf 
Internal Medicine G Microbiology, University vf Bvescia, ltaiy 
Objectives and methods: In an open, randomized (ratio 1:l). 
prospective study the clinical and bacteriologic efficacy and safety of 
nieropenem (MEM) was assessed and compared with that of 
iiiiipenem/cilastatin (IMP/CIL) in 97 hospitalized elderly patients 
(pts) (41 M, 56 F, age range 68-92 years) with community-acqulred 
pneumonia (CAP). Clinical and bacteriologic responses were assessed 
at the end of therapy and at follow-up ( 2 4  weeks). 48 pts received 
MEM (500 mg t i d .  IV) and 49 pts IMP/CIL (500 mg t.i.d. IV). 
Results: In 82 cases (40 in the MEM group and 42 in the 
IMP/CIL group) causative germs were isolated: 38 Gram positive 
(Staphylococcus aureus 12 cases, Streptococcus pneumonia 26) and 44 Gram 
negative (Haernoplzilus spp. 15 cases, Pwudomonas aenrfinosa 6, 
Klebriella pnrumoniar 11, Escherickia cofi 4, Moraxella catarukalis 8). At 
the end of therapy both groups of pts had highly satisfactory clinical 
responses (92% MEM, 89% IMP1CIL). High rates of cure or 
improvement were also seen at the 2-4-week follow-up in both 
groups (90% MEM, 86% IMP/CIL). The mean total cost of thera- 
peutic antibiotic administration for each pt was $1655?141 in the 
MEM group and $1 8742 172 in the IMP/CIL group. Both agents 
showed good activity in microbiologicalal assessments against Gram- 
negative and Gram-positive pathogens. More pts treated with MEM 
(90%) achieved a satisfactory bacteriologic response than pts treated 
with INT/CIL (86%). The difference in favor of MEM (86% versus 
80%) was also observed a t  the 2-4-week follow-up. The drugs were 
well tolerated and side effects occurred in 3% of cases. 
Conclusions: This study shows that MEM is an effective and 
well-tolerated drug and is as effective as IMP/CIL in the treatment 
of CAP. 
HIV-epidemiology, opportunistic infections I 
(p273( Hepatic infection markers in HIV-infected IDUs 
in Russia 
M. Bobkova, N. Detkova, E. Buravtsova, V. Pokrovsky. Russian 
AIDS Center, Moscow, Russia 
Objectives: To refine the data on the prevalence of hepatitis B and 
C among HIV-infected intravenous drug users in Russia. 
Methods: The sera from 262 HIV-infected IDUs (mostly asymp- 
tomatic with regard to HIV and hepatic infections, age group 18-25, 
drug use duration 0.5-2 years) collected in Tver, Kaliningrad, 
Rostov, Nizhny Novgorod and Krasnodar were analyzed by EIA for 
the presence of antibodies to HCcAg, HBcAg, HbcAg, as well as 
HBsAg, HfleAg and HCV RNA. 
Results: The figures obtained are presented in the table. No 
samples of59 PCR analyzed were revealed as HCV positive by HCV 
KT-PCR only. 97.8% of sera were found positive by a t  least one 
hepatitis marker, either HBV or HCV No samplet were negative 
in all tests simultaneously. 65.7% (621106) of patients had mixed 
infection with both HCV and HBV (at least one iiiarker of e ~ c h  
hepatitis). 
\Marker\ anti t HCV 1 anti \ anti 1 H B S h  JHBeAzl 
Conclusions: Widespread hepatic viral infections as well as the 
extremely high percentage of mixed infections are of principdl inter- 
est. The prevalence ofearly hepatitis markcrs in IDUs may result from 
the short duration of drug usage. The most striking fact is thc alnmst 
total absence of hepatitis-free IDUs. This fact must be taken into 
account when designing the course of therapy for these patients. 
lp2741 Pneumonitis in patients infected with HIV in 
the protease inhibitors era: a survey in a 
northeastern Italian area 
M. Libanore, E. Prim, M. Marino, S. Bontempell~, M.K. Rossi, F. 
Ghinelli. Departments vflnfertious Diseasa and Micdio/o'q~ St A r m  
Huspiral, Ferrara, ltaly 
Objectives: To evaluate the incidence of pneumonia in HIV-poai- 
tive patients admitted to a hospital in northeastern Italy. 
Methods: All HIV-positive patients hospitalized in our depart- 
ment from January 1997 to August 1998 were analyzed fix the kind 
of pneumonia, age, gender, HIV rlsk factor, prophylaxis, C114 
Iyniphocyte count, culture and direct examination of sputum and 
blood specimens. Clinical symptoms, chest X-ray, antiretroviral ther- 
apy and clinical outcome were evaluated for each patient. 
Results: O f  the 152 HIV-pocitive patients hospitalized, 56 
(36.8%) came to our attention because ofpneumonia; 40 were inales 
and 16 females (mean age 40.7 years, range 26-85); 37 drug addicts, 
15 heterosexuals, 3 homosexuals and 1 hemophlliac; 18 patients had 
full-blown AIDS (32.1%). The mean count of CD4 cells was 
103.6/mm'. The etiology of pneumonia was: general bacteria in 31 
patients (55.3%), J? (arinii in 12 patients (21.4%), M.  pneunro,liae in 9 
patients (16.1%), atypical mycobacteriosir in 7 patients (12.5%), M.  
tnbercrrlosis in 3 patients (5.3%), Asperfillus spp. in 2 patients (3.h'%)), 
cytomegalovirus in 2 patients (3.6%), and L. pneumoplda and nL: aster- 
oidrs in 1 patient (1.8%)). 10 patients displayed multiple simultaneous 
infections. Patients with PCP had a mean CU4 ccll count of 
36.6/mm3 (range 1-103), and patients with bacterial pncunionia had 
99.3/1nm' (range 1-1122). 11 cases were AIDS: 10 for PCI' and 1 
for tuberculosis. At admission, 17.8% of the patients had received 
anti-PCP prophylaxis and 32.1% were already under antiretroviral 
therapy: 11/18 under triple therapy two nucleoside anaIoR and one 
protease inhibitor), 3/18 with the combination of two nucleoside 
analogs, and 4/18 with single therapy (3 AZT and 1 114T). The inci- 
dence of symptoms In the considered patients was: fever 92.8?4, 
productive cough 38.5%, unproductive cough 7.496, dyspnea 39.3'%1, 
chect pain 25%, cyanosis 8.9%, and hemoptysis 3.6%. 30.3'%1 of the 
patients died during hospitalization 
